CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.
Segal NH, Melero I, Moreno V, Steeghs N, Marabelle A, Rohrberg K, Rodriguez-Ruiz ME, Eder JP, Eng C, Manji GA, Waterkamp D, Leutgeb B, Bouseida S, Flinn N, Das Thakur M, Elze MC, Koeppen H, Jamois C, Martin-Facklam M, Lieu CH, Calvo E, Paz-Ares L, Tabernero J, Argilés G.
Segal NH, et al. Among authors: flinn n.
Nat Commun. 2024 May 15;15(1):4091. doi: 10.1038/s41467-024-48479-8.
Nat Commun. 2024.
PMID: 38750034
Free PMC article.
Clinical Trial.